ATE376547T1 - Derivate des indol-typs als p38 kinase inhibitoren - Google Patents

Derivate des indol-typs als p38 kinase inhibitoren

Info

Publication number
ATE376547T1
ATE376547T1 AT00939322T AT00939322T ATE376547T1 AT E376547 T1 ATE376547 T1 AT E376547T1 AT 00939322 T AT00939322 T AT 00939322T AT 00939322 T AT00939322 T AT 00939322T AT E376547 T1 ATE376547 T1 AT E376547T1
Authority
AT
Austria
Prior art keywords
noninterfering
independently
hydrogen
substituent
noninterfering substituent
Prior art date
Application number
AT00939322T
Other languages
English (en)
Inventor
Babu Mavunkel
Sarvajit Chakravarty
John Perumattam
Sundeep Dugar
Qing Lu
Xi Liang
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,761 external-priority patent/US6589954B1/en
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE376547T1 publication Critical patent/ATE376547T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
AT00939322T 1999-05-21 2000-05-19 Derivate des indol-typs als p38 kinase inhibitoren ATE376547T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/316,761 US6589954B1 (en) 1998-05-22 1999-05-21 Compounds and methods to treat cardiac failure and other disorders
US15459499P 1999-09-17 1999-09-17
US20260800P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
ATE376547T1 true ATE376547T1 (de) 2007-11-15

Family

ID=27387611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939322T ATE376547T1 (de) 1999-05-21 2000-05-19 Derivate des indol-typs als p38 kinase inhibitoren

Country Status (20)

Country Link
EP (1) EP1178983B1 (de)
JP (1) JP2003500403A (de)
KR (1) KR100743377B1 (de)
CN (1) CN1310906C (de)
AT (1) ATE376547T1 (de)
AU (2) AU772295B2 (de)
BG (1) BG106091A (de)
BR (1) BR0011274A (de)
CA (1) CA2372567A1 (de)
CZ (1) CZ20014126A3 (de)
DE (1) DE60036868D1 (de)
HR (1) HRP20010854A2 (de)
HU (1) HUP0201261A3 (de)
IL (1) IL146309A0 (de)
MX (1) MXPA01011976A (de)
NO (1) NO20015655L (de)
NZ (1) NZ515285A (de)
PL (1) PL352032A1 (de)
SK (1) SK16482001A3 (de)
WO (1) WO2000071535A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
WO2001064676A2 (en) * 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE60125980T2 (de) 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
WO2002044168A2 (en) * 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CZ303750B6 (cs) * 2001-02-02 2013-04-17 Bristol-Myers Squibb Company Prostredky obsahující substituované deriváty azaindoloxoacetylpiperazinu a jejich antivirová aktivita
CA2460347A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
WO2003022274A2 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003041644A2 (en) * 2001-11-09 2003-05-22 Scios Inc. Method to treat cystic fibrosis
IL161940A0 (en) * 2001-11-22 2005-11-20 Ono Pharmaceutical Co Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
RU2004132847A (ru) * 2002-04-05 2006-08-20 Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) Способ лечения гиперсекреции слизи
GB0209818D0 (en) 2002-04-30 2002-06-05 Koninkl Philips Electronics Nv Antenna arrangement
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
EP1539121A4 (de) 2002-08-29 2008-08-13 Scios Inc Verfahren zur forderung der osteogenese
JP2006506346A (ja) * 2002-09-03 2006-02-23 サイオス インク． ｐ３８キナーゼ阻害剤としてのインドール系誘導体
CN1713910A (zh) * 2002-10-09 2005-12-28 西奥斯股份有限公司 作为p38激酶抑制剂的氮杂吲哚衍生物
AU2003299652A1 (en) * 2002-12-06 2004-06-30 Scios Inc. Methods for treating diabetes
PL214032B1 (pl) 2003-03-03 2013-06-28 Array Biopharma Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004247626B8 (en) 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
US20070010529A1 (en) * 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
PL1981851T3 (pl) 2006-01-31 2012-07-31 Array Biopharma Inc Inhibitory kinazy i sposoby ich stosowania
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008024391A1 (en) * 2006-08-22 2008-02-28 Scios Inc. Pharmaceutical formulations of an indole-type derivative and related methods of use
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
AR072008A1 (es) * 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
EP2445877B1 (de) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclische verbindungen und verfahren zu deren herstellung und deren verwendung
CN103391718A (zh) 2010-12-06 2013-11-13 汇合生命科学股份有限公司 取代的吡啶酮-吡啶基化合物
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US8563558B2 (en) 2010-12-06 2013-10-22 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
WO2013086208A1 (en) 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
CN108478579B (zh) 2013-06-07 2021-05-25 阿克拉里斯医疗股份有限公司 吡啶酮-吡啶基化合物及其用途
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
PL3691620T3 (pl) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. Inhibitory kinazy p38 zmniejszają poziom ekspresji genu dux4 i dalszych genów do leczenia fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN115666566A (zh) 2020-03-27 2023-01-31 阿克拉瑞斯治疗股份有限公司 用于免疫病况的治疗的mk2途径抑制剂的口服组合物
CN115745864A (zh) * 2021-09-03 2023-03-07 深圳零一生命科技有限责任公司 吲哚类化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283248A (en) * 1989-11-21 1994-02-01 Hoffmann-La Roche Inc. Amino substituted pyrimido[1,6-2]benzimidazoles
CA2028530A1 (en) * 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
JP2001506230A (ja) * 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JP2002515891A (ja) * 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
ATE316961T1 (de) * 1998-05-22 2006-02-15 Scios Inc Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
JP2002523448A (ja) * 1998-08-28 2002-07-30 サイオス インコーポレイテッド ｐ３８−αキナーゼのインヒビター

Also Published As

Publication number Publication date
KR100743377B1 (ko) 2007-07-30
BG106091A (en) 2002-06-28
EP1178983A1 (de) 2002-02-13
SK16482001A3 (sk) 2002-04-04
CA2372567A1 (en) 2000-11-30
CN1310906C (zh) 2007-04-18
CZ20014126A3 (cs) 2002-03-13
NZ515285A (en) 2004-01-30
MXPA01011976A (es) 2002-05-06
KR20020019919A (ko) 2002-03-13
HUP0201261A2 (en) 2002-08-28
PL352032A1 (en) 2003-07-28
DE60036868D1 (de) 2007-12-06
BR0011274A (pt) 2002-02-26
NO20015655D0 (no) 2001-11-20
WO2000071535A1 (en) 2000-11-30
JP2003500403A (ja) 2003-01-07
CN1351599A (zh) 2002-05-29
AU772295B2 (en) 2004-04-22
AU5442400A (en) 2000-12-12
IL146309A0 (en) 2002-07-25
AU2004203356A1 (en) 2004-08-19
EP1178983B1 (de) 2007-10-24
HUP0201261A3 (en) 2003-12-29
NO20015655L (no) 2002-01-18
HRP20010854A2 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
ATE376547T1 (de) Derivate des indol-typs als p38 kinase inhibitoren
WO2002042292A3 (en) Indol derivative and their use as inhibitors of p38 kinase
HUP0302173A2 (hu) Protein kináz inhibitorokként alkalmazható pirazolvegyületek
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301167A2 (hu) Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
ATE296821T1 (de) Triarylimidazol-derivate als cytokin-inhibitoren
DE69933573D1 (de) Chinazolinderivate als medikamente
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO20066015L (no) Fuserte heterosykliske forbindelser
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
ATE211740T1 (de) Substituierte indazolderivate
HUP0203422A2 (hu) Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
EE05035B1 (et) 1-[fenüül-(8-kinolinüül)metüül]piperasiini derivaadid ning nende kasutamine meditsiinis
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
IL175675A0 (en) Tricyclic 1-[(3-indol-3-yl)carbonyl] piperazine derivatives as cannabinoid cb1 receptor agonists
HUP0301553A2 (hu) Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére
HUP0303249A2 (hu) Gombaellenes hatású vízoldékony triazolvegyületek és ezeket tartalmazó gyógyszerkészítmények
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
SE9904177D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties